Evidence map›Paper›PMID 40149320›Full record

ReviewCancers2025

Ex-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis.

Jenny Zipprick, Enes Demir, Hanna Krynska, Sıla Köprülüoğlu, Katharina Strauß, Marcus Skribek, Rita Hutyra-Gram Ötvös, Annica K B Gad, Katalin Dobra

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jenny ZipprickDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.ORCID 0009-0001-1880-3261
Enes DemirDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.ORCID 0000-0003-0950-7740
Hanna KrynskaDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.ORCID 0000-0002-3759-3503
Sıla KöprülüoğluDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.ORCID 0009-0007-0168-3199
Katharina StraußDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.
Marcus SkribekDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.ORCID 0000-0001-8692-6426
Rita Hutyra-Gram ÖtvösDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.
Annica K B GadDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.ORCID 0000-0002-1098-9129
Katalin DobraDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

3D-organoid cell culturedrug sensitivity testinglung cancerpersonalized medicinepleural mesotheliomatargeted treatment

Identifiers

PMID40149320
PMCPMC11940109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.